Checking In On The Housing Market… And The Future of Pharma & Health Care 2/18/25

18 Feb 2025 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Summary: CNBC's "Fast Money" Episode Title: Checking In On The Housing Market… And The Future of Pharma & Health Care Air Date: 02/18/25

---

Episode Overview In this episode of "Fast Money," hosted by Melissa Lee, the discussion centers around the current state of the housing market, highlighted by a drop in builder sentiment, as well as the future of the pharmaceutical and health care sectors amidst funding cuts and organizational changes.

Key Topics Discussed

Housing Market Insights

  • Builder Sentiment Decline
  • Builder sentiment has dropped to a five-month low.
  • Concerns over rising tariffs and their impact on the housing market were emphasized.
  • Toll Brothers Earnings Report
  • Performance Overview
  • Toll Brothers reported a significant decline in revenues (down 5% year-over-year) and missed Wall Street's earnings and delivery expectations.
  • CEO Doug Yearly noted the sales pressure at the lower end of the market due to affordability issues despite healthy demand at the higher end.
  • Market Conditions
  • The average sale price of homes in Q1 was approximately $925,000.
  • Discussions among analysts pointed towards a potential plateau for homebuilders due to tariff impacts and rising interest rates.
  • General Sentiment
  • Experts debated whether higher interest rates would continue to affect the housing market negatively and if the industry would stabilize moving forward.
  • Concerns were raised regarding the overall economic picture, particularly employment, as it relates to home building.

Pharmaceutical and Health Care Sector Analysis

  • Funding Cuts and Personnel Changes
  • Health agencies are facing significant funding cuts and restructuring, leading to a focus on how the pharmaceutical industry will adapt.
  • Mark Cuban's Perspective
  • Mark Cuban discussed his venture, Cost Plus Drugs, which aims to provide medications at lower prices by eliminating middlemen.
  • Cuban urged for better collaboration with pharmaceutical companies to challenge big pharmacy benefit managers (PBMs).
  • Investment Outlook
  • There was a general consensus that only certain pockets of the pharmaceutical sector might be worthwhile investments, with attention drawn to companies like Gilead and Johnson & Johnson.
  • Analysts expressed caution regarding the pricing pressures faced by pharma companies due to regulatory changes and potential tariffs.

Broader Market Performance

  • Record Highs for Major Indices
  • The S&P 500 reached new intraday and closing highs, with discussions centered around what might be driving this rally despite negative sentiment in specific market sectors.
  • Sector Rotation
  • Analysts pointed out ongoing rotations within technology and financial sectors, with mixed performances noted in stocks like Intel, Alibaba, and Wynn Resorts.

Key Takeaways

  • The housing sector is facing pressures from rising interest rates and tariffs, potentially limiting growth in the near term.
  • The pharmaceutical industry is currently grappling with significant changes in policy and funding, creating both challenges and opportunities for investors.
  • Despite negative sentiments in certain sectors, the overall market has continued to perform well, suggesting a bifurcation in market performance.

Conclusion The episode presented critical insights into the housing market and the pharmaceutical sector, with expert discussions highlighting both current challenges and future opportunities. The contrasting performance of different sectors within the financial markets suggests a complex economic landscape moving forward.

---

*For more detailed information, visit [CNBC Fast Money](http://fastmoney.cnbc.com).*

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:01Live from the NASDAQ market site in the heart of New York City's Times Square. This is Fast Money. And here's what's on tap for tonight. Housing headaches, shares of Toll Brothers sinking, as you can see, after the company's latest earnings report. That after a dismal day overall for the builders. We're going to dig in on the numbers and bring you the trade on the housing space. And back at records, the S &P setting its first intraday and closing record high since late January. What's driving the move? And is there more gas left in the tank for stocks? We're going to debate it. Plus, a baba bounce takes the stock to three-year highs.

0:36Investors bet on a win-for-win resorts. And Meta breaks a historic winning streak. What's next for the social giant? I'm Dominic Chewin from Melissa Lee this afternoon, coming to you live from Studio B at the NASDAQ market site. On the desk tonight, Dan Nathan, Guy Adami, Carter Worth, and Julie Beal. Let's get right to the markets. The S &P is staging a late-day rally to set new record intraday and closing highs, As you can see there, it's the first time since late January. The Dow and the Nasdaq, by the way, also inching back towards records of their own. We're going to get to all of that in just a few minutes time.

1:09But we start with an earnings alert on Toll Brothers. The homebuilder sharply lower after missing Wall Street's earnings and delivery expectations estimates. Our Diana Olek joins us with all the relevant numbers. Diana. Well, Dom, it was kind of an ugly first quarter for the luxury homebuilder. Missing on the top and bottom lines. Toll also came in short on deliveries. Revenue down 5 % year over year. CEO Doug Yearly said in the release that the miss was mostly due to some impairments and a delay in the sale of an apartment property in a joint venture. He said home building operations met expectations.

1:39He did, however, add that although demand has remained healthy in many of our markets and particularly at the higher end, affordability constraints and growing inventories in certain markets are pressuring sales, especially at the lower end. The average sale price in Q1 for toll was$925 ,000. He also said that based on first quarter results, the gross margin embedded in their backlog and the trends they're seeing early in the spring selling season, they are reaffirming all key homebuilding guidance for the full year, including deliveries, average price and adjusted gross margin. There was nothing in the release about the potential impact of tariffs.

2:15We'll look to hear more on that on the analyst call tomorrow morning. But, Dom, as you know, homebuilder sentiment this morning tanked because of tariffs. And that was down to a five months low from the National Association of Homebuilders. It's all going to be part of that contextual picture. Diana, thank you very much for all of that. Let's turn now to what's going to happen with the trade here on the home builders. And maybe, Guy, I'll start with you on this. If you take a look at the way things have moved, the sentiment numbers, as Diana alluded to, had tariffs front and center. Do we think that there is a plateau building for home builders?

2:48Before we even get into it, welcome. We're a welcoming show. It's good to be back with you guys. So welcome, Dom. Am I right, Dan? 100 percent, Guy. Appreciate that. I think it's a big deal. I think tariffs are the headline. Interest rates, though, are probably the real plot. And when you look at the Toll Brothers, average selling price is now down 8 % year over year. So in my opinion, higher rates are starting to have an impact. And you look at this stock, I mean, the move we've had since November has been significant. And to me, it's not about EPS. It's not about if these stocks are expensive.

3:18It's cheap. What do you think about the employment picture? And what do you think about the rate picture? I think the employment picture is going to deteriorate. I think rates are going to go up. So almost by definition, you can't own these. Now, if you put a chart up, you'll see 110 or so was the level that we bounced from in July of last year. That should be support. That's probably where we're headed. Yeah, it's worth noting, though, it's not just obviously home builders. It's also the autos, right? And so they're facing this headwind of potential tariffs here. And if you go back and you're just calling up charts here today, aren't we?

3:48Yes, we do. Let's look at the GM chart for a second. It doesn't look too different than where Toll Brothers topped out, too. It was late November. So lots of sectors rally over the enthusiasm about a pro-growth sort of agenda by the new administration. But I think, you know, first and foremost, I think tariffs have basically taken over, like, the story here as it relates to our economy. And that's the sort of thing where you talk about the S &P, you talk about the Dow making new highs. At some point, these sectors that face these headwinds are going to weigh on S &P 500 earnings, even if it's just indecision, right, whether it be from consumers or it might be indecision from companies and CEOs and how they choose to spend their money on R &D and CapEx.

4:29Julie, if we talk about the fundamentals of the housing market, this is a key point in the overall scheme of the year and maybe even this market right now. It's the spring selling season. We're almost into it. How worrying is Toll Brothers and how worrying is the homebuilders trade if you look at it from that standpoint? Well, I think for sure it's pretty critical that right now they get out there and be able to make up for the mistakes that they had. They reaffirmed their guidance. And so I think they have a certain amount of confidence. They have a certain amount of their inventory that's already bought and paid for and sold.

5:00So I think that their visibility is probably better than the average home builder. And also demographically speaking, they're better positioned because they're a higher end builder. I'm much more worried about the lower end entry level building companies because I think they're even more economically sensitive. Exactly to Guy's point, the employment picture is what's really going to drive them longer term. That's what we really need to see. I think tariffs are something that can be an intermediate or short term headwind for them, but they've all been able to be pretty resilient in the face of that.

5:33Hey, Carter, are any of these charts set up better than others, either one way or the other, if you could find some momentum or some carry through to the upside or down? It's a very homogeneous group, of course. And what we know is that they are all under pressure and they all peaked as four, five, six months ago. In fact, the S &P 500 home building sub-industry group right now is down 30 percent from its peak in September. And you have a sort of a one-two setup that's not good. The one is that this group has doubled the performance of the S &P over the past decade, the past 15, 20 years, and now is underperforming.

6:12So when you have something that's been a massive outperformer that then starts to stall and roll over, all of these stocks qualify as bullish to bearish reversal sells. And the news out with toll bothers doesn't help the situation. You know, Julie, I want to go back to something you said with regard to some of these, the spectrum across there. One thing that we do know is that many of the housing related stocks outside of the pure builders, I'm thinking names like Home Depot or Lowe's or maybe names like Masco on the building supply side of things, have been trading alongside, maybe not exactly lockstep, but they're not exactly momentum upside winners at this point either.

6:49How big of a deal is it for some of those other plays like a Home Depot or Lowe's, given the fact that the housing market right now seems to be losing at least a little bit of steam for the time being? Yeah, I mean, I think it's absolutely critical, right? All of those businesses, everyone has been holding their breath. If you read any analyst note covering any of these companies for all of 2024, we're just waiting for interest rates to decline. And we're all just waiting and waiting and holding our breath. Eventually, we're not going to be feeling so great. I think the biggest concern for everyone is that affordability remains a very large problem in the home sector.

7:24And we just don't have a lot of visibility in terms of when interest rates are really going to soften. There's just more factors pushing them up than down. About a week and a half or so ago, I thought that Home Depot could break out through those December, I think, 2021 highs. And it looked like it was poised to do it. It has not traded well ever since, should come as no surprise to Fast Money fans. I put the maloic on it. But with that That said, this report on the 25th becomes extraordinarily important in terms of where the stock is technically and maybe where it is on a valuation level as well.

7:58So, you know, these downstream plays, which have seemingly been Teflon, potentially could be under a lot of pressure as well. All right. So with that in mind, let's turn back to the broader markets overall, because the major indices are closing near their highs of the day right now. The S &P setting, by the way, new intraday and closing records. The Nasdaq is less than a percent off its high, while the Dow eked out a gain of 10 points. So for more on what's been driving and what's next for the markets, let's bring in Katerina Simonetti of Morgan Stanley Private Wealth Management. Katerina, what does it say to you that we're having this generally negative conversation right now about a key part of the market and the economy, yet the Nasdaq is a percent away from record highs, the Dow is a little over a percent from record highs, and the S &P is at record highs right now?

8:44Well, Dom, the market has been extremely positive over the last couple of weeks, which is unusual, especially for the month of February that has been historically volatile. And when we're thinking about the backdrop of the tariff fears and executive orders and higher bond yields, it is almost interesting to see this development. And perhaps it is the possibility of the war ending. Perhaps there is a general sense that countries will have to step up, or maybe it's just the healthy economic dread drop that we have been experiencing over the last couple of years. But markets seems to be quite opportunistic.

9:29It's not just that, Katerina. If you take a look at yields, we talk about interest rates so often as a driving force behind these markets. We are still markedly lower than we were just a few weeks ago in terms of the 10-year Treasury yield. It's a benchmark for mortgage lending and elsewhere as well. What exactly is the rate importance for the overall market? Do we need to see continued rate gradual declines on the long end of things in order for this market to keep going higher? Well, we definitely have an extremely data driven Fed. And as we are kind of deciphering the news and are trying to see if tariff conversation, is this a policy or is it a negotiating tactic?

10:10Once we see the actual effect that higher for longer narrative has in the economy, Federal Reserve is going to figure out the way to proceed. We're expecting two rate cuts this year, perhaps one in May and one in September. But in our view, there are so many factors that are going to go into it. And perhaps we're just seeing the broadening of the market. Last couple of years, the leadership of the market has been in technology and seeing other sectors like health care, like energy, manufacturing, software, you know, on the tech side, you know, coming in and leading the way, you know, is something that could be affecting this market as well as high yields.

10:51Do you think that broadening out trade plays out markedly so in 2025, Katarina? Do we see names like financials continue to outperform? Energy was an outperformer today, albeit on higher oil prices. Does that rotation trade still happen? Dom, it was a surprise to so many investors that technology was not the leading sector in 2024. It was, in fact, financials. Financials ended up being up 32 percent in 12 months. And we are going to see more of this as quality stocks are going to be leading the way. There's a lot of fear. There's a lot of uncertainty. But there's also a lot of opportunity in quality names, both here in the U.S.

11:31and also in Europe. Katarina, at 4%, nobody seems to be concerned about the labor market, the unemployment rate. Are there any cracks in the armor that you see? Or is this basically, you know, we're in this great environment for the labor market and therefore theoretically a great environment for the market? We have not seen full employment at this level for quite some time. Is it playing a role in overall data, you know, as we're located? Of course. And it also is giving investors that sense of comfort with the market. But we can't forget about the fact that we're coming off of the two extremely positive years, unusually positive.

12:09So there has to be realistic expectations of what this year is going to bring. Even with the healthiest economic backdrop, we're probably looking at the low single digit returns for the end of the year. How fearful, Katerina, do your clients, investors in general, have to be about a renewed inflationary threat this year? You laid out the case for maybe two rate cuts this year, but it sure seems like the near-term data suggests inflation is certainly not gone. Of course, inflation has been a major concern for us throughout the 24, and we know without shadow of a doubt that tariffs are inflationary.

12:44Now, we have to wait and see what this tariff policy is actually going to end up being. But inflation was a concern, will be a concern and absolutely is going to have the negative effect on the market. And this is where investors absolutely are concerned. So when we're looking at the sectors, we will need to be significantly more selective about our stock picking this year versus just investing in the broad market index and just seeing how things play out. All right. Katerina Simonetti, Morgan Stanley, Private Wealth. Thank you very much. We'll see you soon. Thank you for having me. All right, Dan, given what she just said, are there favorite sectors that you should be in, given the backdrop that we've seen develop?

13:28We're seeing rotations within tech. And again, you know, out of semis, semis have really been flat over the last six months or so. Obviously, NVIDIA and Taiwan Semi have been big outperformers, but it can't get the SOX, the SOXX going at all. Next week is going to be obviously important when we get NVIDIA's earnings. And obviously, I think the whole sector should likely trade with it. On a day like today, though, I look at the fateful eight, right? I don't see many of them up. You know, NVIDIA was up three and a half percent at one point today. I think it closed up 40 basis points. Microsoft closed up a little bit.

13:58The rest were down. And you look at software and it's doing pretty well. So you're seeing a bit of rotation within tech. But when you look at some of these other areas that we just talked about, some pockets in the industrial space, home building, obviously financials have trade pretty well. So that's on the flip side of what we've seen or what we've just been talking about, the ones that are kind of seeing rates as a headwind. And so 4.5 % up in the S &P 500 year to date. We had two consecutive years of 25 % returns. Something's got to happen if we're going to kind of get to double-digit returns.

14:27I think that Katerina just said they're expecting low single-digit gains this year. Well, you know what? We're up low single digits right now. So it'll be interesting to see how we get there. The last thing I'll just say is this. Both the Bank of America Global Fund Manager surveyed. 89 % or so of the respondents said they're like full up in cash. Like they don't have cash on the sidelines. That seems a little euphoric right here. All right, Julie, what does this setup say to you? Does it feel like there's no gas left? There's no fuel left in the tank at this point? I think there is fuel left in the tank.

15:00I think because we've seen enough weakness in earnings outside of the Magnificent Seven that there's still opportunity for growth. But it really is requiring everything to go right. And I think that's the kind of concern that we're all feeling is that there are enough difficulties in front of the markets. and in front of just companies writ large, that they have uncertainty, they have inflation, they have interest rates. And these are the types of things that can really trip up companies when we're trying to navigate this landscape. And so I think it's really natural to look at this market, at this pricing, at these levels and say, gosh, we really could use a nice pullback in terms of being able to level set and reflect where we are as far as the fundamentals.

15:42All right. Well, speaking of navigating, folks, President Trump is signing some executive orders just in the last hour. CNBC's own Megan Casella has all those details. And these EOs are becoming a fact of life in the first hundred days of the administration. What exactly do we need to know now and how do we have to navigate these new EOs? Almost every day there's some new ones down. So a couple of executive orders and a press conference down in Florida just in the last hour. The first order was a move directing Trump's Domestic Policy Council to look for ways to expand access to fertility treatments and to make IVF and other treatments more affordable.

16:20He also then signed a presidential memorandum, so one step down from an order, committing to what he called radical transparency. This one directs his agencies to release the complete details of every program and contract that they cancel as they work to streamline the government. So something to look for there as Doge begins to work its way through federal agencies. Trump then also spoke a bit about tariffs, saying that he will be announcing more specifics on his sectoral tariffs after April 2nd, but that tariffs on cars and pharmaceuticals are likely to start at 25 percent and could go higher from there.

16:55Then on the Doge front, Trump said that he has no concerns about the thousands of layoffs of probationary employees across federal agencies this weekend. And even he was specifically asked about the layoffs of people who focus on nuclear weapons security who were immediately then rehired. No concerns about how that was done. He was also asked about the potential for a conflict of interest as Doge works with the FAA and the Defense Department, given Elon Musk's and SpaceX contracts that are in place. Trump said that anything to do with space, he will not let Musk partake in that. And then finally, Dom, as Trump walked away from the cameras, he said that he would probably meet with Russian President Vladimir Putin before the end of the month.

17:35That came just a few minutes after Trump said that what he wants with Russia and Ukraine is peace and that he thinks he has the power to end this war. So much more to watch on that front as well. Dom. All right. Thank you very much, Megan Gisela, for a lot of detail and recapping of these new EOs and memorandum. So this is important, Guy. As we talk about the navigation aspect of it, we have to deal with this idea that there are uncertainties that need to be addressed by the markets vis-a-vis the administration. What exactly does that do to, say, investor sentiment, given what we've seen now so far?

18:09Well, apparently investor sentiment is not great. Apparently, the lowest I've seen in about a year and a half. And yet records are at record highs. My next point. So, I mean, clearly the market has figured out how to sort of deal with this and handicap it. So with the VIX below 16, the S &P had effectively at an all-time high. I mean, the market doesn't seem to care. We'll talk about it all the time, and rightly so, but the market has figured out how to handicap this. I will say this, though. It does come down to interest rates. And, you know, you look at the move in interest rates, and all the things that we continue to hear are not bullish for the bond market.

18:41In other words, they're not reason for rates to go lower, the reason for the rates to go higher. That, to me, is the real story of this market. All right. Thanks very much, guys. Coming up with the show, a potential breakup boost. Shares of Intel surging on reports competitors could be looking to split the company up. What a deal could look like coming up next. And don't look now, but Alibaba is up nearly 50 % in just 2025 alone. Founder Jack Ma resurfacing in a high-profile meeting with China's Xi Jinping. The latest on the Chinese tech trade. When Fast Money returns, we are back in two. You're watching Fast Money here on CNBC.

19:20We'll be right back.

19:31All right. Welcome back to Fast. Intel shares surging more than 16 % following a Wall Street Journal report that rivals Broadcom and Taiwan Semi are exploring independent deals to split up the chip maker. Broadcom is reportedly interested in acquiring Intel's chip design and marketing business, while Taiwan Semi wants either partial or complete control of its factories or foundry business. Intel is up more than 36 % this year after today's gains, but have been nearly cut in half since the start of 2024. Dan, this is one that is in your Gen AI acronym, as we are seeing up there right now. So take us through the Intel pieces.

20:10By the way, I played the game right, Guy. You see what I did there? Some of the folks on this desk don't do it. But what I was trying to do here is kind of go after some laggards. And this action is pretty interesting. Guy's been making the case, I think, for a couple years that Intel is too important of an American company just to continue to flounder like this. And so when you see what's going on, it's really a shame that the Biden administration didn't come around to this kind of quicker. I think they gave them maybe$8 or$9 billion as part of the Chips Act. That wasn't going to do anything.

20:36They don't have a CEO right now. That chip design business is probably more than three quarters of the value of this company. I think that's one of the main reasons why the stock has rallied the way it has from maybe$20 to where it's trading like 27 or something like that. There's a gap to be filled above of that. Any way you look at this thing, that some of the parts is probably a bit higher. I think it's gone too far, too fast. I'd be really surprised if we get any announcements in the near term. These sorts of things without a CEO in place are probably pretty hard to navigate. Carter, you've got to put these things in contest.

21:06We're flashing all kinds of timelines for charts here, massive moves that we're seeing very much in the green. But if you look longer term, it's a very different story. So what do the charts say to you about whether Intel has more room to run? Sure. I mean, that's just it. Timeframes. It's ever thus, and one has to know who one is in the market and what one's time frame is. We know that this stock still is way below its dot-com peak, up in the 70s. It's right now a$27 stock, still down some 60%. And yet what we also know is it's been basing and bottoming for the better part of 10 months. It keeps holding 18, 19, 18, 19.

21:41Now it's thrust aggressively on heavy volume from that 18, 19 level to where we are at 27. And we are into the gap that I guess Guy referred to. That was a drop in gap on earnings on the 1st of August. And so a natural sort of resting spot, if you will, for this current day-to-day thrust would be to fill that gap. That's not much higher. That's at 30, 31. At that point, you would be back to a level of overhead supply. And if I were in this stock and had caught this move, I would be cutting it back by half above 30. Guy, this is interesting. Speaking of volumes, I mean, this thing right now, it looks like as things are settling out, has traded about 260 million shares today.

22:25The 10-day average is roughly 116 million. There was a lot of activity today. Yeah, almost three times normal. We'll call it two and a half times normal volume. Absolutely. Dan was kind to say I've been pointing that out. He was also kind enough to point out I've been saying it since it was a$50 stock. So it's been wrong. But with that said, I mean, if you look technically, the latest low we made is a bit of a double bottom from the fall. Nothing's been fixed at Intel. I want to be crystal clear, but the stock can still go higher. And Carter and Dan are right to point out those levels. 31 gets us back to levels that we broke down from in July of last year.

23:00I think that's where it's headed. Then we'll have another conversation. All right. There's still a lot more to come here on Fast Money. So here's what's coming up on the show. Quite the bounce for Alibaba. the Chinese tech stock trading at three-year highs. Will support from Beijing help the rally keep running? Plus, the future of healthcare in America. What billionaire investor Mark Cuban has to say about the space. You're watching Fast Money, live from the NASDAQ market side in Times Square. We're back right after this.

Read the full transcript

23:37Welcome back to Fast Money. The Alibaba shares are popping almost 2%, bringing the tech giant year-to-date gains to nearly 50%. I can't believe I'm saying this. The stock hit levels today not seen since February of 2022. Founder Jack Ma making a rare appearance at a business symposium, as you're seeing there, hosted by none other than Chinese President Xi Jinping on Monday. The pair is seen here shaking hands as Beijing starts to show some more support for the country's private sector and maybe tech giants in particular, Kai. It wasn't that long ago. We were talking about the all-out assault of the Chinese Communist Party on their tech industry.

24:19Can we put that picture? Can we, our crack staff and EC put that picture back? Are those, what do they call those members-only channels? Is that what they're rocking? That is like a, you mean Chinese President Xi Jinping? I mean, that's a good look, man. It is, but it doesn't have that members-only logo. Yeah, maybe they're not allowed to rep. No, I don't know. Look, as well, we talked about acronyms before, so I'll throw you mine. The tube, the B in the tube, as you probably well aware, is Alibaba, which is killing it this year. We're seeing it right there. And there's, you know, despite the fact that the stock is going, I think, from 82 to a buck and a quarter, there's still room in this name of people like you're out of your mind.

24:53Maybe. Now, the good news is they report on Thursday, and maybe they'll say something will scare some people. Maybe they'll get an opportunity to buy it cheaper. But Alibaba, and I've said this now for a while, should be a$140 stock, Don. Yeah, I think we've got to get a little more clarity about what Apple's going to be doing with Alibaba. Obviously, Baidu, not obviously, but Baidu's been thrown in there, too, as somebody who might be participating in Apple intelligence. And when you think about that, that's really the story right now, right? So to me, you know, the country, you know, President Xi, I mean, they sat on these companies.

25:23These are their national championship for all intents and purposes. And they've got a lot of room to go, I mean, from a stock perspective. But they also have to prove to the world that they are basically on par with what we have over here, despite the fact that our digital companies, for all intents and purposes, can't be there. But the story of Apple intelligence, the story of U.S. multinationals going in and partnering with Alibaba and Baidu, to me, means there's more room to run. But I would actually probably be focused on Baidu, despite the fact that they gave some disappointing guidance here today.

25:53Carter, can we believe it? Can we believe the near to medium term momentum that we've seen in some of these Chinese tech giants? Or is this just going to lead to more tears, kind of like the last couple of years had? Right. So we have this is the second go at it. Right. We'll recall that, of course, in September and it was a very appreciative thing. Tepper came out and said, by all things Chinese. And what you had was a huge surge in Hang Seng, up some 40 percent and Baba up 60. And that peaked on the 7th of October almost to give 60, 70 percent of it back. Now, if you were to look at the hang saying we're right back to the penny to that October 7th high, whereas Bhabha is through the high.

26:35The presumption is that there's room to run. And, of course, if one wants to dream, one can look at the five-year chart of Alibaba and look back and see how high it's been and how much ground it still has potentially to recoup losses. All right. Coming up on the show, what billionaire investor Mark Cuban has to say about the next move in pharma and how our traders are handling the stock moves in that space when Fast Money returns after this break. Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.

27:19Welcome back to Fast Money. Stocks managing some small gains to kick off a holiday-shortened trading week. The S &P closing at a record high. The Dow and the Nasdaq ending slightly higher as well in the day. Meta's record run finally coming to an end after a 20-day winning streak. Those shares dropping nearly 3 % to end that 20-day streak, which started a month ago. That was the longest run ever, ever of any stock currently in the S &P 500. So I alluded to historic earlier on. It is quantitatively so. Shares of Howard Hughes giving back its late day gains after hours. Bill Ackman's Pershing Square announcing a revised proposal for the real estate development company saying it would buy 10 million shares for 90 bucks apiece.

28:04And some more after hours action. Occidental Petroleum beating earnings expectations but missing revenue estimates. and Devon Energy posting earnings and revenues that beat expectations. Both companies also increasing their quarterly dividends. Devon higher by three quarters of a percent, Occidental down by one and a half percent. Now, as the nation's health agencies grapple with funding cuts and major personnel changes, pharma industry leaders are convening in Washington, D.C. to lay out their policy goals in the year ahead. Our own Angelica Peebles is at the Pharma Industry Lobbying Group's Commitment to a Healthier America event, where she just sat down with Cost Plus Drugs founder and, of course, billionaire investor Mark Cuban.

28:47Angelica, what can you tell us? Hey, Dom, that's right. We are here. And of course, PBMs are a big focus of the pharmaceutical industry. Now, Mark Cuban three years ago launched his Cost Plus Drugs, and the idea there is that he sells the drugs that he buys for just the cost that he bought them for in a 15 % markup. And, you know, Mark Cuban telling me at this point that it's been pretty successful, but so far they've really only been able to sell generics. And it's going to take a lot more to get the branded companies, the companies that are selling the branded drugs, to work with him. As we convince those CEOs to move away from the big PBMs, so you've seen Box.com, Tyson Foods, AT &T, and a growing list of others, probably 22 million lives covered.

29:34If we can get 60, 70 million lives covered, then it's okay for Merck and others to say, look, we're not beholden to those big PBMs any longer. Now, I know it's a health care conference, but I did have to ask about the big Mavericks trade that has been very controversial. I asked Mark if he's regretting his decision to sell his majority stake in the Mavs. And he laughed and he said no. He said that he is really enjoying spending time with his kids. And he's happy that he can protect them from the, quote, hell and hatred that happens if you make a mistake, which made me pause and ask if it was in fact a blunder.

30:11I would have done it differently, but you know what? They paid me a lot of money to make those choices. And Patrick's smart. I know Patrick's been getting a lot of crap. I know Nico's been getting, but they're good people. And they do have the best interests of the Mavericks at heart. And before he left, I did have to ask if he thinks that there's any chance that the Mavs leave Dallas. And he laughed and said no. Dom. You covered it all, Angelica. Thank you very much for that. And good luck with this travels here from Washington, D.C. You hit it all. Angelica Peoples, thank you very much for that.

30:42Julie, let's get out to you about this. The Pharma Industry Conference here puts a big spotlight on an industry right now that is very front and center for folks watching what the Trump administration will do. What exactly does this tell you about whether or not pharma is investable in 2025? I think only pockets of it are investable, and I think even that is pretty challenging. I think early indications are that tariffs could be happening in pharma, but that doesn't really tell us a lot about our existing drugs and pharma companies writ large. I think the outlook right now is pretty uncertain, and I don't view it as a super investable class.

31:20I would rather own businesses that serve pharma companies. I think that the pricing situation is such and so opaque with the PBMs that we could see more and more pressure on pricing going forward in the U.S. Guy, what do we think? Well, a couple of names have been unbelievable. Gilead is within a few dollars of an all-time high made 10 years ago. I think analysts are way off sides. I think Deutsche Bank just upgraded the name. You're going to see more and more people do that around some of these FDA rulings that have been in their favor, number one. And J &J, if you're looking for value, massive double bottom around 144 or so.

31:53I think J &J could give you some upside over the next couple of weeks, too. Carter, what do you think? Well, it's a very, Julie makes this point, it's only pockets. So we know that the sub-industry group, S &P 500 Pharmaceuticals, is the big three. That would be, of course, Pfizer and Merck-Lily, but you've also got Bristol-Myers, J &J. What's interesting is that the relative performance of this group to the market is at 30-year lows. I mean, it's incredible with all the heavy lifting that Lilly's done. So the question is, is this sort of deep value or is it a contrarian bet? But my hunch is, yes, an overweight here makes sense.

32:28Guy, we love Mark Cuban, don't we? Friend of the show for a long time. Mark Cuban has been watching his show since the inception. One of the first guests we had, a friend of ours, a friend of the show, absolutely. What he's doing in the pharma space, pretty cool. She asked him about the Luka trade. You know, the Mavericks lost in the finals last year. Boston Celtics kind of smoked them a little bit, right? Not a little bit. A lot of it, right? That team valued at$5 billion, the Mavericks. Celtics are trading here. What do you think, Guy? Matt Brax. I like what you did there. North of seven? What do you think?

33:00North of seven billion? Yeah, there's going to be an NBA team that goes for 10 billion over the next three to five years. Without question. You think it's the Celtics or what? If they win this year, they've got a little bit of dynasty? Could you? Yeah. Well, they're not going to win this year, unfortunately. There's a team down the street about eight blocks from here that look poised to take over that crown. That, of course, would be the Knickerbockers of New York with Jalen Brunson, as Dan knows, playing point guard. Yeah, but the Celtics went into the garden. I'm going to ask one question, and then both of you guys can answer very quickly.

33:31Simultaneously? Not simultaneously. Are the Mavs better off without Luka? No way. Yes. Really? They didn't think he was. They don't like his dad bod, but you rock a dad bod. They don't like his dad bod. I'm 61 years old. I can rock a lot of things at 61. I can't drain it from three like Luca. Nobody can. On that note, Dom. All right, guys. Coming up on the show here, Wall Street and the calls that had Wynn hitting blackjack. And then, of course, hims and hers, shares thinning out, if you will. We've got the details in those trades coming up next when Fast Money returns after this.

34:29Welcome back to Fast Money. We've got a pair of calls of the day for you. Let's start with the casino operator, Wynn Resorts, continuing to climb after an upgrade by analysts at Jefferies. The stock is up another 2.75 % today after last week's earnings pop. Up analysts are raising the stock to a buy rating from neutral and upping their target price to 118 a share. That's about 30 percent upside from current levels. Guy, do you believe the Wynn Resort store? I do. I mean, if you look at this chart as well, I mean, it's have some ups and downs. But valuation, if Tim was here, he'd say the same thing.

34:59It's just too cheap. Now, I understand why it sold off over the last year or so. Some China scares, Macau scares, but it's a valuation story here. So, yeah,$91. This stock, to me, should be easily back to the levels we saw. I want to say October 105. Dan, it's not just about valuations. In that note, if you believe the analysts, they say that there are growth potentials for Macau and for its U.S. properties for Wynn as well. So it's not just valuation. There's a growth story. Yeah. Focused on Macau, though, and we know that that's been a disproportionate amount of revenues over the last, I don't know, called 10 years or so.

35:33And obviously, Vegas and some of the other areas in the U.S. are going to be big growth areas if they can ever get it going. I think the Macau issue really speaks more to the Chinese consumer, right? And so we've just seen, obviously, some of these names like PDD and Alibaba. Maybe that has more to do with their cloud business and what they're doing with Apple. But I think Wynn and the rally here could keep on going the way that Baba has if we got some sense that there's going to be more stimulus for the Chinese consumer. So Wynn seems like a pretty decent one to play right here. All right. So that stock is up.

36:04Meanwhile, check out shares of HIMS and HERS, that health company, that recently Red Hot Health Company, its stock is down right now 3.5 % after a downgrade from Morgan Stanley. Analysts are cutting the stock to an equal weight or neutral, but upping their target price to$60 to kind of catch it up. Morgan Stanley is saying that it's time for a breather. The stock's had a run so far this year that's been pretty decent. Even with today's pullback, the telehealth stock is still up a whopping 140%. So, Julie, is this a stock that you want to stick with or heed the call and just pull back? I think if you're going to be sticking with it, you need to be investing in Tums while you're at it because I think you're up for a pretty bumpy ride.

36:44It's not just that the fundamentals of this business are a little bit still to be figured out. Part of it, too, is a regulatory issue. What will the Trump administration's viewpoint on compounders be? Will there still be a GLP-1 shortage that enables them to continue to sell that business? We know that a lot of the growth is really being driven on the women's side, the hers business. And so in order to kind of maintain that level of growth, you have to have confidence in both of those things. And I don't know if I necessarily do. And the problem is, is that you have a very high level of short interest.

37:17So I think regardless, volatility is up ahead for this one. It also trades at 110 times forward earnings at this point right now. So Carter, what do you think about the charts on this one here? Well, extended, right? I mean, that's not very clever in terms of a comment, but it is more extended than it's been at any time in the past three, five years. You're some 150 percent above the 150 moving average. It's also, to Julie's point, very volatile. It's had, count them, four instances where it's dropped more than 35 percent in the past year and a half. And that's the exact kind of thing that happens here when you're this far above trend.

37:54All right. That's the story for him's and hers and Wynn. And coming up on the show, a technical take on overseas investing, what the Chartmaster sees for opportunities outside of America. That's coming up next. And here's a sneak peek at the Kramer cam. Jim's chatting right now exclusively with the CEO of electronics manufacturer Jabel. Catch that full interview at the top of the hour on Mad Money with Jim Kramer. We got more Fast Money in two minutes time.

38:28Welcome back to Fast Money. Even as the S &P sets new records, global markets are outpacing America, believe it or not, this year. The MSCI World Index is up 5 % in 2025. The stock 600 in Europe is up nearly 10%. So is it time to broaden your portfolio overseas? Let's turn now to the chart master for a lesson in the technicals global edition. Carter. Right, and the DAX is up even more than that with SAP being the biggest contributor. Let's go right to the charts and try to look at the relationship between the world and the world without the U.S. So these are very straightforward colors and straightforward lines.

39:05One is the MSCI All-Country World Index, ACWI. And the other in orange is the All-Country World Index. But you strip out the U.S. stocks, the big heavy winners. And so you'll see here since inception of the indices back in the late 80s, this is almost a four-bagger. Now, this is the same chart, but depicted as a ratio chart. And what it shows, of course, is that the MSCI X, the U.S., has been underperforming since 2009 low, but it did outperform in 2001 to 2007. So let's go right to the here and now chart. So this is since 2009, and it's straight down. It's a perfect 45-year-old down and to the right.

39:46It is the underperformance of the world index X the U.S. versus the world index itself, which, of course, includes the U.S. I've drawn an up arrow there. I think we're going to go to the upper band of that down channel. And then one more iteration just to put it together. We have ricocheted nicely off the bottom, off the top, off the bottom. And on this last go, we undercut the lower band for the first time. And then finally, one index or one bourse, this is the Indian stock exchange, the Sensex. It is down to support, down some 15%, 18%. I think you play for a bounce here. Okay. There is a world in charts.

40:22You speak Portuguese? I do not speak Portuguese. Neither do I. Obrigado. Yes. Tutubum? Yes. Tutubum. Put up an EWZ chart, and this one's Tutubum. And I'll tell you, this, Dan, help me with the name because you remember these things. We're at the iConnections conference. A gentleman sat next to me. Martin Escobar. Yes. Yeah, Atlantic. And he talked, I asked him about the EWZ and he said, completely undervalued. Look at what that stock has done or that ETF has done since. And we are on the verge of breaking out of a 17-year downtrend. So if you want to be one place, it's EWZ there, Dom. What do we think, Dan?

41:00You know, it's a tough one. And I think Martin Escobar said this. Like, it's about transparency. It's a tough one there. They have a lot of the political headwinds there. They have inflationary issues. Sometimes they get hyperinflationary. super inflationary. I mean, this is not particularly interesting to me. I'd probably look at the EEM. It's got Chinese exposure. It's got a bunch of other exposure, you know, in and around South America and the like. So to me, EEM is more interesting than EWZ. All right. And what about Carter? Last word to you. The Germany trade. It's intriguing. Yes. Again, that is the big constituent within the stocks 600 Europe and SAP is what's driving that.

41:37Of course, it's the big tech name. But the relationship between the DAX and the stock 600, it's fairly stretched. I think one fades SAP and by inference is underway Germany relative to the rest of Europe. All right. There's the global take there. Thanks, everybody. Coming up next, your final trade. So keep it right here.

42:06All right, it's about that time. It's final trades to go around the horn. Julie, starting with you. Celsius, C-E-L-H. I think the bad news is past us, and for long-term investors, could be a good one. All right, Carter. Silver, lagging gold, but its time is now. We think it breaks out here. Ooh, hi-ho silver. Dan. Yeah, if you like China, you'll like EEM, top three holdings, Taiwan Semi, guys B in the tube. That would be the Alibaba, Tencent, this one, EEM. All right, Guy Adami. Shout out to Mark Cuban, who doesn't have a dad, Bob. He's also a fan of the show. You're going to run this bleep back tomorrow with you?

42:43We're going to run it back. There we are. Let's do it. J &J dominate. All right. Thanks, everybody, for watching Fast Money. Mad Money with Jim Cramer starts right now. We'll see you guys tomorrow here.

43:22consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Fast Money Disclaimer, please visit cnbc.com forward slash Fast Money Disclaimer.

From the publisher

A check in on the housing market, as builder sentiment drops to a 5-month low. The concerns they have over looming tariffs, and the latest results out of one of the top players in the space. Plus Pharma in focus, as the country’s health agencies deal with funding cuts and personnel changes. How industry execs are positioning, and what billionaire investor Mark Cuban is saying about the future of the space.

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Checking In On The Housing Market… And The Future of Pharma & Health Care 2/18/25CNBC's "Fast Money" · 44 min
Listen in VO